[144] Centessa Pharmaceuticals plc SEC Filing

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) Form 144 notice: This filing reports a proposed sale of 6,000 common shares to be executed through UBS Financial Services on Nasdaq with an aggregate market value of $130,860 and an acquisition date of 09/15/2025 by exercise of stock options paid in cash. The filer previously sold multiple blocks of common shares during the past three months: 12,000 on 06/24/2025 for $168,218.40; 6,000 on 07/15/2025 for $89,566.80; 6,000 on 08/15/2025 for $103,380.00; and two larger sales on 09/09/2025 and 09/10/2025 of 20,000 shares each for $400,102.00 and $440,000.00 respectively. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• None.

Negative

• Repeated insider sales: The filer sold multiple blocks totaling 64,000 shares in the past three months, which could be viewed unfavorably by some investors.
• Planned immediate sale after option exercise: The 6,000 shares to be sold were acquired by exercise on the same date, suggesting immediate monetization rather than long-term retention.
• Filing lacks residual ownership disclosure: The notice does not state remaining holdings or whether sales are pursuant to a 10b5-1 plan, limiting context for the transactions.

Insights

Securities Analyst

TL;DR: Concentrated insider selling occurred recently, and an additional 6,000-share sale is planned after option exercise.

The filing documents an upcoming Rule 144 sale of 6,000 common shares acquired the same day by exercising options and paid in cash, to be executed on Nasdaq via UBS. The transaction follows several recent dispositions by the same individual totaling 64,000 shares sold across June–September 2025 with aggregate reported proceeds above $1.2M. For investors, recurring insider sales may warrant monitoring but the filing alone does not disclose motives, remaining ownership levels, or material nonpublic information.

Corporate Governance Expert

TL;DR: Multiple Rule 144 disclosures indicate routine monetization of holdings rather than a single isolated sale.

The notice properly lists the broker, class, acquisition method (exercise of stock options), payment method (cash), and prior sales in the past three months with dates and gross proceeds. From a governance perspective, documentation appears to comply with Rule 144 disclosure requirements; however, the filing does not include details on residual holdings or any trading plan adoption date, so it is not possible to determine whether sales were pre-planned under Rule 10b5-1.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. Eleven Madison Avenue 4th Floor New York NY 10010	6000	130860.00	134073436	09/15/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2025	Exercise of Stock Options	Issuer			6000	09/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	06/24/2025	12000	168218.40
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	07/15/2025	6000	89566.80
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	08/15/2025	6000	103380.00
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	09/09/2025	20000	400102.00
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	09/10/2025	20000	440000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CNTA Form 144 filing report?

It reports a proposed Rule 144 sale of 6,000 common shares acquired by option exercise on 09/15/2025, with aggregate market value of $130,860, to be sold via UBS on Nasdaq.

How many shares did the filer sell in the past three months for CNTA?

The filer reported sales totaling 64,000 common shares across 06/24/2025 to 09/10/2025 (12,000; 6,000; 6,000; 20,000; 20,000).

What were the gross proceeds from recent CNTA insider sales?

Reported gross proceeds include $168,218.40, $89,566.80, $103,380.00, $400,102.00, and $440,000.00 for each listed sale.

Were the 6,000 shares acquired by gift or purchase?

They were acquired by exercise of stock options on 09/15/2025 and paid in cash.

Which broker will execute the planned CNTA sale?

The sale is to be executed through UBS Financial Services Inc., Eleven Madison Avenue, New York.